J&J signs stem cell type 1 diabetes deal with ViaCyte – PharmaTimes

J&J signs stem cell type 1 diabetes deal with ViaCytePharmaTimesJohnson & Johnson has linked up with ViaCyte with a view to getting rights to the stem cell specialist's investigational treatment for type 1 diabetes. A deal has been inked giving J&J's Janssen unit a future right to evaluate a transaction related ...and more
http://blog.zandcell.com/jj-signs-stem-cell-type-1-diabetes-deal-with-viacyte-pharmatimes/?utm_source=rss&utm_medium=rss&utm_campaign=jj-signs-stem-cell-type-1-diabetes-deal-with-viacyte-pharmatimes